Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?

Rosario Sanguedolce, Carlo Pavone, Rossana Porcasi, Anna Calascibetta, Rosa Maria Tomasino, Anna Calascibetta, Rossana Porcasi, Rosario Sanguedolce, Darwin Melloni, Michele Pavone-Macaluso

Risultato della ricerca: Article

2 Citazioni (Scopus)

Abstract

Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. The monoclonal antibody JSB1 (DBA) at 1:20 dilution was employed for the GP-170 assay. Results: GP-170 expression increases with grade but was lower in multiple tumours. No difference between Ta and T1 categories was detected. GP-170 immunohistochemistry from different portions of the same tumour showed a very marked variability in 35.7% of patients. Seven patients (11.6%) were totally negative for GP-170. No statistically significant correlation was found between recurrence, progression and GP-170 basal expression. Similarly no correlation emerged between grade and stage variations at recurrence and modifications in GP-170 expression. One third of the tumours recurring after chemotherapy were negative for GP-170 in spite of an increase in recurrence rate and other risk factors. Conclusion: At the present stage of our experience, we have been unable to show that GP-170 is a useful marker for monitoring chemoresistance to intravesical chemotherapy in superficial bladder cancer. Furthermore, GP-170 determination has shown several technical difficulties.
Lingua originaleEnglish
pagine (da-a)2971-2976
Numero di pagine6
RivistaAnticancer Research
Volume22
Stato di pubblicazionePublished - 2002

Fingerprint

Transitional Cell Carcinoma
P-Glycoprotein
Urinary Bladder
Recurrence
Urinary Bladder Neoplasms
Drug Therapy
Immunohistochemistry
Neoplasms
Pharmaceutical Preparations
Monoclonal Antibodies
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cita questo

Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder? / Sanguedolce, Rosario; Pavone, Carlo; Porcasi, Rossana; Calascibetta, Anna; Maria Tomasino, Rosa; Calascibetta, Anna; Porcasi, Rossana; Sanguedolce, Rosario; Melloni, Darwin; Pavone-Macaluso, Michele.

In: Anticancer Research, Vol. 22, 2002, pag. 2971-2976.

Risultato della ricerca: Article

Sanguedolce, R, Pavone, C, Porcasi, R, Calascibetta, A, Maria Tomasino, R, Calascibetta, A, Porcasi, R, Sanguedolce, R, Melloni, D & Pavone-Macaluso, M 2002, 'Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?', Anticancer Research, vol. 22, pagg. 2971-2976.
Sanguedolce, Rosario ; Pavone, Carlo ; Porcasi, Rossana ; Calascibetta, Anna ; Maria Tomasino, Rosa ; Calascibetta, Anna ; Porcasi, Rossana ; Sanguedolce, Rosario ; Melloni, Darwin ; Pavone-Macaluso, Michele. / Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?. In: Anticancer Research. 2002 ; Vol. 22. pagg. 2971-2976.
@article{3fa2ebdbfeaa4343934f3c45d5ecafe0,
title = "Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?",
abstract = "Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. The monoclonal antibody JSB1 (DBA) at 1:20 dilution was employed for the GP-170 assay. Results: GP-170 expression increases with grade but was lower in multiple tumours. No difference between Ta and T1 categories was detected. GP-170 immunohistochemistry from different portions of the same tumour showed a very marked variability in 35.7{\%} of patients. Seven patients (11.6{\%}) were totally negative for GP-170. No statistically significant correlation was found between recurrence, progression and GP-170 basal expression. Similarly no correlation emerged between grade and stage variations at recurrence and modifications in GP-170 expression. One third of the tumours recurring after chemotherapy were negative for GP-170 in spite of an increase in recurrence rate and other risk factors. Conclusion: At the present stage of our experience, we have been unable to show that GP-170 is a useful marker for monitoring chemoresistance to intravesical chemotherapy in superficial bladder cancer. Furthermore, GP-170 determination has shown several technical difficulties.",
author = "Rosario Sanguedolce and Carlo Pavone and Rossana Porcasi and Anna Calascibetta and {Maria Tomasino}, Rosa and Anna Calascibetta and Rossana Porcasi and Rosario Sanguedolce and Darwin Melloni and Michele Pavone-Macaluso",
year = "2002",
language = "English",
volume = "22",
pages = "2971--2976",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",

}

TY - JOUR

T1 - Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?

AU - Sanguedolce, Rosario

AU - Pavone, Carlo

AU - Porcasi, Rossana

AU - Calascibetta, Anna

AU - Maria Tomasino, Rosa

AU - Calascibetta, Anna

AU - Porcasi, Rossana

AU - Sanguedolce, Rosario

AU - Melloni, Darwin

AU - Pavone-Macaluso, Michele

PY - 2002

Y1 - 2002

N2 - Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. The monoclonal antibody JSB1 (DBA) at 1:20 dilution was employed for the GP-170 assay. Results: GP-170 expression increases with grade but was lower in multiple tumours. No difference between Ta and T1 categories was detected. GP-170 immunohistochemistry from different portions of the same tumour showed a very marked variability in 35.7% of patients. Seven patients (11.6%) were totally negative for GP-170. No statistically significant correlation was found between recurrence, progression and GP-170 basal expression. Similarly no correlation emerged between grade and stage variations at recurrence and modifications in GP-170 expression. One third of the tumours recurring after chemotherapy were negative for GP-170 in spite of an increase in recurrence rate and other risk factors. Conclusion: At the present stage of our experience, we have been unable to show that GP-170 is a useful marker for monitoring chemoresistance to intravesical chemotherapy in superficial bladder cancer. Furthermore, GP-170 determination has shown several technical difficulties.

AB - Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. The monoclonal antibody JSB1 (DBA) at 1:20 dilution was employed for the GP-170 assay. Results: GP-170 expression increases with grade but was lower in multiple tumours. No difference between Ta and T1 categories was detected. GP-170 immunohistochemistry from different portions of the same tumour showed a very marked variability in 35.7% of patients. Seven patients (11.6%) were totally negative for GP-170. No statistically significant correlation was found between recurrence, progression and GP-170 basal expression. Similarly no correlation emerged between grade and stage variations at recurrence and modifications in GP-170 expression. One third of the tumours recurring after chemotherapy were negative for GP-170 in spite of an increase in recurrence rate and other risk factors. Conclusion: At the present stage of our experience, we have been unable to show that GP-170 is a useful marker for monitoring chemoresistance to intravesical chemotherapy in superficial bladder cancer. Furthermore, GP-170 determination has shown several technical difficulties.

UR - http://hdl.handle.net/10447/201354

M3 - Article

VL - 22

SP - 2971

EP - 2976

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

ER -